Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience (SKYE)
NASDAQ:SKYE
SKYE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $7.11
Previous CloseN/A
Volume18.00K
Average Volume (3M)306.40K
Market Cap
$108.46M
Enterprise Value$117.56M
Total Cash (Recent Filing)$48.59M
Total Debt (Recent Filing)$367.54K
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Nov 06, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding30,988,420
10 Day Avg. Volume212,495
30 Day Avg. Volume306,398
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-194.07
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$15.50Price Target Upside358.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Data PresentationSkye will present results supporting that CB1 inhibition is sufficient to promote weight loss using clinical data at the European Congress on Obesity.
Clinical Study ProgressThe Phase IIa CBeyond study will continue as the fourth Data Safety Monitoring Committee convened without raising any safety concerns.
Financial StabilityThe company ended 2024 with $68.4 million in cash, which is expected to fund operations through at least the first quarter of 2027.
Bears Say
Financial PerformanceSkye reported a net loss of $9.7 million, which was in line with estimates but still represents a financial loss.
Trial Data ReleaseThe interim data from the Phase IIa CBeyond trial will no longer be released as initially planned.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience’s price range in the past 12 months?
Skye Bioscience lowest stock price was $1.14 and its highest was $7.11 in the past 12 months.
What is Skye Bioscience’s market cap?
Skye Bioscience’s market cap is $108.46M.
When is Skye Bioscience’s upcoming earnings report date?
Skye Bioscience’s upcoming earnings report date is Nov 06, 2025 which is in 63 days.
How were Skye Bioscience’s earnings last quarter?
Skye Bioscience released its earnings results on Aug 07, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.12.
Is Skye Bioscience overvalued?
According to Wall Street analysts Skye Bioscience’s price is currently Undervalued.
Does Skye Bioscience pay dividends?
Skye Bioscience does not currently pay dividends.
What is Skye Bioscience’s EPS estimate?
Skye Bioscience’s EPS estimate is -0.3.
How many shares outstanding does Skye Bioscience have?
Skye Bioscience has 30,988,420 shares outstanding.
What happened to Skye Bioscience’s price movement after its last earnings report?
Skye Bioscience reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went down -0.845%.
Which hedge fund is a major shareholder of Skye Bioscience?
Currently, no hedge funds are holding shares in SKYE
Skye Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (358.58% Upside)
$15.50 (358.58% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.39%
12-Months-Change
Fundamentals
Return on Equity
-72.75%
Trailing 12-Months
Asset Growth
-40.22%
Trailing 12-Months
Company Description
Skye Bioscience
Skye Bioscience (SKYE) is a biotechnology company focused on the discovery, development, and commercialization of innovative pharmaceutical products intended to address unmet needs in various therapeutic areas. The company primarily operates in the biopharmaceutical sector, with a core emphasis on ocular diseases. Skye Bioscience is committed to advancing its pipeline of cannabinoid-derived compounds, leveraging its proprietary technologies to develop novel treatments that have the potential to improve patient outcomes.
SKYE Company Deck
SKYE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of Skye Bioscience's progress. While the company showcased significant advancements in its clinical trials and financial stability, it also faced challenges with increased R&D expenses and a substantial net loss. The strategic developments and promising preclinical data are positive highlights, but the enrollment challenges in the extension study indicate areas needing attention.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$15.50
▲(358.58% Upside)
Technical Analysis
Alterity Therapeutics
―
Actinium Pharmaceuticals
―
Mersana Therapeutics
―
Celularity
―
OnKure Therapeutics
―
Ownership Overview
66.72% Insiders
4.91% Mutual Funds
0.95% Other Institutional Investors
23.69% Public Companies and Individual Investors